Financials data is unavailable for this security.
View more
Year on year COSCIENS Biopharma Inc had revenues fall -20.25% from 5.64m to 4.50m, though the company grew net income from a loss of 22.73m to a smaller loss of 16.55m.
Gross margin | 39.42% |
---|---|
Net profit margin | -278.95% |
Operating margin | -365.76% |
Return on assets | -26.11% |
---|---|
Return on equity | -45.58% |
Return on investment | -30.53% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at COSCIENS Biopharma Inc fell by 16.60m. However, Cash Flow from Investing totalled 528.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 17.12m for operations while cash used for financing totalled 151.00k.
Cash flow per share | -9.43 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 11.61 |
---|---|
Tangible book value per share | 10.14 |
More ▼
Balance sheet in USDView more
Current ratio | 3.36 |
---|---|
Quick ratio | 3.05 |
Total debt/total equity | 0.0643 |
---|---|
Total debt/total capital | 0.0604 |
More ▼